BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, Hayashi N, Aogi K, Ishida T, Masuoka H, Iijima K, Masuda S, Tsugawa K, Kinoshita T, Nakamura S, Tokuda Y. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry. Annals of Oncology 2016;27:480-7. [DOI: 10.1093/annonc/mdv611] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Kawai M, Tomotaki A, Miyata H, Iwamoto T, Niikura N, Anan K, Hayashi N, Aogi K, Ishida T, Masuoka H, Iijima K, Masuda S, Tsugawa K, Kinoshita T, Nakamura S, Tokuda Y. Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry. Cancer Med 2016;5:1328-40. [PMID: 26923549 DOI: 10.1002/cam4.678] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
2 Masuda S, Nitta H, Kelly BD, Zhang W, Farrell M, Dennis E. Intratumoral Estrogen Receptor Heterogeneity of Expression in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer as Evaluated by a Brightfield Multiplex Assay. J Histochem Cytochem 2019;67:563-74. [PMID: 31184528 DOI: 10.1369/0022155419856862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 Mohan SC, Walcott-Sapp S, Lee MK, Srour MK, Kim S, Amersi FF, Giuliano AE, Chung AP. Alterations in Breast Cancer Biomarkers Following Neoadjuvant Therapy. Ann Surg Oncol 2021. [PMID: 33748896 DOI: 10.1245/s10434-021-09814-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Pizzuti L, Krasniqi E, Sperduti I, Barba M, Gamucci T, Mauri M, Veltri EM, Meattini I, Berardi R, Di Lisa FS, Natoli C, Pistelli M, Iezzi L, Risi E, D’ostilio N, Tomao S, Ficorella C, Cannita K, Riccardi F, Cassano A, Bria E, Fabbri MA, Mazzotta M, Barchiesi G, Botticelli A, D’auria G, Ceribelli A, Michelotti A, Russo A, Salimbeni BT, Sarobba G, Giotta F, Paris I, Saltarelli R, Marinelli D, Corsi D, Capomolla EM, Sini V, Moscetti L, Mentuccia L, Tonini G, Raffaele M, Marchetti L, Minelli M, Ruggeri EM, Scavina P, Bacciu O, Salesi N, Livi L, Tinari N, Grassadonia A, Fedele Scinto A, Rossi R, Valerio MR, Landucci E, Stani S, Fratini B, Maugeri-saccà M, De Tursi M, Maione A, Santini D, Orlandi A, Lorusso V, Cortesi E, Sanguineti G, Pinnarò P, Cappuzzo F, Landi L, Botti C, Tomao F, Cappelli S, Bon G, Pelle F, Cavicchi F, Fiorio E, Foglietta J, Scagnoli S, Marchetti P, Ciliberto G, Vici P. PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. Ther Adv Med Oncol 2021;13:175883592110598. [DOI: 10.1177/17588359211059873] [Reference Citation Analysis]
5 Altunay B, Morgenroth A, Mottaghy FM. Use of Radionuclide-Based Imaging Methods in Breast Cancer. Semin Nucl Med 2022:S0001-2998(22)00034-4. [PMID: 35624034 DOI: 10.1053/j.semnuclmed.2022.04.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Li A, Keck JM, Parmar S, Patterson J, Labrie M, Creason AL, Johnson BE, Downey M, Thomas G, Beadling C, Heiser LM, Kolodzie A, Guimaraes AR, Corless CL, Gray JW, Mills GB, Bergan RC, Mitri ZI. Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. NPJ Precis Oncol 2021;5:28. [PMID: 33772089 DOI: 10.1038/s41698-021-00165-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Oroujeni M, Rinne SS, Vorobyeva A, Loftenius A, Feldwisch J, Jonasson P, Chernov V, Orlova A, Frejd FY, Tolmachev V. Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake. Int J Mol Sci 2021;22:2770. [PMID: 33803361 DOI: 10.3390/ijms22052770] [Reference Citation Analysis]
8 Hernandez S, Lazcano R, Serrano A, Powell S, Kostousov L, Mehta J, Khan K, Lu W, Solis LM. Challenges and Opportunities for Immunoprofiling Using a Spatial High-Plex Technology: The NanoString GeoMx® Digital Spatial Profiler. Front Oncol 2022;12:890410. [PMID: 35847846 DOI: 10.3389/fonc.2022.890410] [Reference Citation Analysis]
9 Caswell-Jin JL, McNamara K, Reiter JG, Sun R, Hu Z, Ma Z, Ding J, Suarez CJ, Tilk S, Raghavendra A, Forte V, Chin SF, Bardwell H, Provenzano E, Caldas C, Lang J, West R, Tripathy D, Press MF, Curtis C. Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy. Nat Commun 2019;10:657. [PMID: 30737380 DOI: 10.1038/s41467-019-08593-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
10 Golse N, Adam R. Liver Metastases From Breast Cancer: What Role for Surgery? Indications and Results. Clinical Breast Cancer 2017;17:256-65. [DOI: 10.1016/j.clbc.2016.12.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
11 Takahashi R, Nunobe S, Osumi H, Takahari D, Yamamoto N, Ida S, Kumagai K, Ohashi M, Sano T, Hiki N. Clinical outcomes of radical gastrectomy following trastuzumab-based chemotherapy for stage IV HER2-positive gastric or gastroesophageal junction cancer. Surg Today 2020;50:1240-8. [PMID: 32451714 DOI: 10.1007/s00595-020-02011-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Ding J, Hu P, Chen J, Wu X, Cao Y. The importance of tissue confirmation of metastatic disease in patients with breast cancer: lesson from a brain metastasis case. Oncoscience 2016;3:268-74. [PMID: 28050577 DOI: 10.18632/oncoscience.320] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Turner KM, Yeo SK, Holm TM, Shaughnessy E, Guan JL. Heterogeneity within molecular subtypes of breast cancer. Am J Physiol Cell Physiol 2021;321:C343-54. [PMID: 34191627 DOI: 10.1152/ajpcell.00109.2021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F, Giommoni E, Fornaro L, Aprile G, Melisi D, Berenato R, Mennitto A, Volpi CC, Laterza MM, Pusceddu V, Antonuzzo L, Vasile E, Ongaro E, Simionato F, de Braud F, Torri V, Di Bartolomeo M. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. Int J Cancer. 2016;139:2859-2864. [PMID: 27578417 DOI: 10.1002/ijc.30408] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 7.8] [Reference Citation Analysis]
15 Dehdashti F, Wu N, Bose R, Naughton MJ, Ma CX, Marquez-Nostra BV, Diebolder P, Mpoy C, Rogers BE, Lapi SE, Laforest R, Siegel BA. Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. Breast Cancer Res Treat 2018;169:523-30. [PMID: 29442264 DOI: 10.1007/s10549-018-4696-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
16 Ignatov T, Gorbunow F, Eggemann H, Ortmann O, Ignatov A. Loss of HER2 after HER2-targeted treatment. Breast Cancer Res Treat 2019;175:401-8. [DOI: 10.1007/s10549-019-05173-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
17 Saeki H, Oki E, Kashiwada T, Arigami T, Makiyama A, Iwatsuki M, Narita Y, Satake H, Matsuda Y, Sonoda H, Shimokawa M, Maehara Y. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). European Journal of Cancer 2018;105:41-9. [DOI: 10.1016/j.ejca.2018.09.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
18 Rey-Vargas L, Mejía-Henao JC, Sanabria-Salas MC, Serrano-Gomez SJ. Effect of neoadjuvant therapy on breast cancer biomarker profile. BMC Cancer 2020;20:675. [PMID: 32682413 DOI: 10.1186/s12885-020-07179-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Chen HR, Wu YT, Yu QB, Yang YY, Wei YX, Li HY, Wu KN, Kong LQ. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer. World J Surg Oncol 2017;15:189. [PMID: 29052527 DOI: 10.1186/s12957-017-1255-8] [Reference Citation Analysis]
20 Liu Y, Wu S, Shi X, Luo Y, Pang J, Wang C, Mao F, Liang Z, Zeng X. HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor. Breast Cancer Res Treat 2019;178:275-81. [PMID: 31388934 DOI: 10.1007/s10549-019-05387-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
21 Mazari FAK, Sharma N, Dodwell D, Horgan K. Human Epidermal Growth Factor 2–positive Breast Cancer with Mammographic Microcalcification: Relationship to Pathologic Complete Response after Neoadjuvant Chemotherapy. Radiology 2018;288:366-74. [DOI: 10.1148/radiol.2018170960] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
22 Schneider J, Lee HJ, Nam SJ, Lee SJ, Jung JH, Jung SH, Lim ST, Jeon YW, Gwak H. Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients. J Breast Cancer 2020;23:259-67. [PMID: 32595988 DOI: 10.4048/jbc.2020.23.e34] [Reference Citation Analysis]
23 Miao H, Sun Y, Jin Y, Hu X, Song S, Zhang J. Application of a Novel 68Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients. Front Oncol 2022;12:894767. [PMID: 35712499 DOI: 10.3389/fonc.2022.894767] [Reference Citation Analysis]
24 Wetzel CL, Sutton TL, Gardiner S, Farinola M, Johnson N, Garreau JR. Loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes. J Surg Oncol 2021. [PMID: 34416025 DOI: 10.1002/jso.26646] [Reference Citation Analysis]
25 Kazama T, Takahara T, Hashimoto J. Breast Cancer Subtypes and Quantitative Magnetic Resonance Imaging: A Systemic Review. Life 2022;12:490. [DOI: 10.3390/life12040490] [Reference Citation Analysis]
26 Kumar G, Nandakumar K, Mutalik S, Rao CM. Biologicals to direct nanotherapeutics towards HER2-positive breast cancers. Nanomedicine 2020;27:102197. [PMID: 32275958 DOI: 10.1016/j.nano.2020.102197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
27 Kushnarev VA, Kudaibergenova AG, Zavalishina LE. [The use of intralaboratory and external quality control of immunohistochemical studies to improve the detection of estrogen and progesterone receptors]. Arkh Patol 2021;83:5-9. [PMID: 33822548 DOI: 10.17116/patol2021830215] [Reference Citation Analysis]
28 Deken MM, Bos DL, Tummers WSFJ, March TL, van de Velde CJH, Rijpkema M, Vahrmeijer AL. Multimodal image-guided surgery of HER2-positive breast cancer using [111In]In-DTPA-trastuzumab-IRDye800CW in an orthotopic breast tumor model. EJNMMI Res 2019;9:98. [PMID: 31754913 DOI: 10.1186/s13550-019-0564-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
29 Miyashita M, Niikura N, Kumamaru H, Miyata H, Iwamoto T, Kawai M, Anan K, Hayashi N, Aogi K, Ishida T, Masuoka H, Iijima K, Masuda S, Tsugawa K, Kinoshita T, Tsuda H, Nakamura S, Tokuda Y. Role of Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer Patients: A Study from the Japanese Breast Cancer Registry. Ann Surg Oncol 2019;26:2475-85. [DOI: 10.1245/s10434-019-07453-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
30 Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M, Cacciatore M, Genovesi E, De Bartolo D, Vernaci G, Amato O, Porra F, Conte P, Guarneri V, Dieci MV. HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment. NPJ Breast Cancer 2022;8:66. [PMID: 35595761 DOI: 10.1038/s41523-022-00434-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Chun KH, Park JH, Fan S. Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer. Adv Exp Med Biol 2017;1026:59-104. [PMID: 29282680 DOI: 10.1007/978-981-10-6020-5_4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
32 De Mattos-Arruda L, Shen R, Reis-Filho JS, Cortés J. Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nat Rev Clin Oncol 2016;13:566-79. [PMID: 27000962 DOI: 10.1038/nrclinonc.2016.35] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
33 Guan X, Liu B, Niu Y, Dong X, Zhu X, Li C, Li L, Yi Z, Sun X, Chen H, Lu S, Ma F. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer. Breast 2020;49:261-6. [PMID: 31927339 DOI: 10.1016/j.breast.2019.12.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
34 Guerini-rocco E, Botti G, Foschini MP, Marchiò C, Mastropasqua MG, Perrone G, Roz E, Santinelli A, Sassi I, Galimberti V, Gianni L, Viale G. Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement. Tumori. [DOI: 10.1177/03008916211062642] [Reference Citation Analysis]
35 Upadhyaya VS, Lim GH, Chan EYK, Fook-Chong SMC, Leong LCH. Evaluating the preoperative breast cancer characteristics affecting the accuracy of axillary ultrasound staging. Breast J 2020;26:162-7. [PMID: 31562691 DOI: 10.1111/tbj.13635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Goller SS, Markert UR, Fröhlich K. Trastuzumab in the Treatment of Pregnant Breast Cancer Patients - an Overview of the Literature. Geburtshilfe Frauenheilkd 2019;79:618-25. [PMID: 31217630 DOI: 10.1055/a-0880-9295] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
37 Wang RX, Chen S, Jin X, Chen CM, Shao ZM. Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis. Breast Cancer Res Treat 2017;161:259-67. [PMID: 27885439 DOI: 10.1007/s10549-016-4064-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
38 Viale G, Fusco N. Pathology after neoadjuvant treatment - How to assess residual disease. Breast 2021:S0960-9776(21)00990-5. [PMID: 34810049 DOI: 10.1016/j.breast.2021.11.009] [Reference Citation Analysis]
39 Li B, Yau T, Leung R, Kwok G, Tsang J, Cheung P, Wong TT, Suen D, Kwong A, Chiu JW. Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers. Adv Ther 2021;38:5752-62. [PMID: 34699004 DOI: 10.1007/s12325-021-01933-1] [Reference Citation Analysis]
40 Griffin N, Marsland M, Roselli S, Oldmeadow C, Attia J, Walker MM, Hondermarck H, Faulkner S. The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer. Biomolecules 2020;10:E1329. [PMID: 32957504 DOI: 10.3390/biom10091329] [Reference Citation Analysis]
41 Li Q, Xu X, Su D, Zhou T, Wang G, Li Z. Long-term survival of an elderly patient with advanced gastric cancer after combination therapy: a case report and literature review. BMC Cancer 2019;19:459. [PMID: 31096933 DOI: 10.1186/s12885-019-5683-4] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389:2415-2429. [PMID: 27939064 DOI: 10.1016/s0140-6736(16)32417-5] [Cited by in Crossref: 263] [Cited by in F6Publishing: 135] [Article Influence: 43.8] [Reference Citation Analysis]
43 Al-Zeheimi N, Adham SA. Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP-1 and HER2 expression and converted MCF7 breast cancer subtype. Br J Pharmacol 2020;177:2024-41. [PMID: 31883395 DOI: 10.1111/bph.14966] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Hamilton E, Shastry M, Shiller SM, Ren R. Targeting HER2 heterogeneity in breast cancer. Cancer Treat Rev 2021;100:102286. [PMID: 34534820 DOI: 10.1016/j.ctrv.2021.102286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Al-Saleh K, Aldiab A, Salah T, Arafah M, Husain S, Al-Rikabi A, El-Aziz NA. Prognostic Significance of HER2 Expression Changes Following Neoadjuvant Chemotherapy in Saudi Patients With Locally Advanced Breast Cancer. Clin Breast Cancer 2021;21:e362-7. [PMID: 33419688 DOI: 10.1016/j.clbc.2020.11.015] [Reference Citation Analysis]
46 He L, Araj E, Peng Y. HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features. Curr Oncol 2021;28:1608-17. [PMID: 33923191 DOI: 10.3390/curroncol28030150] [Reference Citation Analysis]
47 Wang L, Jiang Q, He MY, Shen P. HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review . World J Clin Cases 2022; 10(1): 260-267 [DOI: 10.12998/wjcc.v10.i1.260] [Reference Citation Analysis]
48 Ab Mumin N, Ramli Hamid MT, Wong JHD, Rahmat K, Ng KH. Magnetic Resonance Imaging Phenotypes of Breast Cancer Molecular Subtypes: A Systematic Review. Acad Radiol 2022;29 Suppl 1:S89-S106. [PMID: 34481705 DOI: 10.1016/j.acra.2021.07.017] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Provenzano E, Pinder SE. Modern therapies and iatrogenic changes in breast pathology. Histopathology 2017;70:40-55. [PMID: 27960235 DOI: 10.1111/his.13098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
50 Rosati D, Giordano A. Single-cell RNA sequencing and bioinformatics as tools to decipher cancer heterogenicity and mechanisms of drug resistance. Biochem Pharmacol 2021;:114811. [PMID: 34673017 DOI: 10.1016/j.bcp.2021.114811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Raimondi A, Nichetti F, Peverelli G, Di Bartolomeo M, De Braud F, Pietrantonio F. Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies. Pharmacogenomics 2018;19:1047-68. [PMID: 30041572 DOI: 10.2217/pgs-2018-0077] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
52 Yoshida A, Hayashi N, Suzuki K, Takimoto M, Nakamura S, Yamauchi H. Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer. J Surg Oncol 2017;116:1021-8. [DOI: 10.1002/jso.24762] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
53 Yu J, Li NL. Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report. World J Clin Cases 2022; 10(17): 5923-5928 [DOI: 10.12998/wjcc.v10.i17.5923] [Reference Citation Analysis]
54 Makiyama A, Sukawa Y, Kashiwada T, Kawada J, Hosokawa A, Horie Y, Tsuji A, Moriwaki T, Tanioka H, Shinozaki K, Uchino K, Yasui H, Tsukuda H, Nishikawa K, Ishida H, Yamanaka T, Yamazaki K, Hironaka S, Esaki T, Boku N, Hyodo I, Muro K. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). JCO 2020;38:1919-27. [DOI: 10.1200/jco.19.03077] [Cited by in Crossref: 30] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
55 Hayashi N, Yagata H, Tsugawa K, Kajiura Y, Yoshida A, Takei J, Yamauchi H, Nakamura S. Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER+ HER2- Breast Cancer: A Prospective Phase II Study. Clin Breast Cancer 2020;20:462-8. [PMID: 33046356 DOI: 10.1016/j.clbc.2020.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
56 Li A, Schleicher SM, Andre F, Mitri ZI. Genomic Alteration in Metastatic Breast Cancer and Its Treatment. American Society of Clinical Oncology Educational Book 2020. [DOI: 10.1200/edbk_280463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. The Lancet Oncology 2019;20:816-26. [DOI: 10.1016/s1470-2045(19)30097-x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 43] [Article Influence: 37.0] [Reference Citation Analysis]
58 Agostinetto E, Debien V, Marta GN, Lambertini M, Piccart-Gebhart M, de Azambuja E. CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer. Eur J Clin Invest 2021;51:e13535. [PMID: 33662161 DOI: 10.1111/eci.13535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Pernas S, Tolaney SM. Targeting HER2 heterogeneity in early-stage breast cancer. Curr Opin Oncol 2020;32:545-54. [PMID: 32925204 DOI: 10.1097/CCO.0000000000000685] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
60 Yang L, Zhang Z, Li J, Chen M, Yang J, Fu J, Bu H, Tang S, Liu Y, Li H, Li X, Xu F, Teng X, Yang Y, Ma Y, Guo S, Wang J, Guo D. A decision tree-based prediction model for fluorescence in situ hybridization HER2 gene status in HER2 immunohistochemistry-2+ breast cancers: a 2538-case multicenter study on consecutive surgical specimens. J Cancer 2018;9:2327-33. [PMID: 30026828 DOI: 10.7150/jca.25586] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
61 Yang L, Zhong X, Pu T, Qiu Y, Ye F, Bu H. Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy. World J Surg Oncol 2018;16:51. [PMID: 29514654 DOI: 10.1186/s12957-018-1332-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
62 Tolmachev V, Orlova A, Sörensen J. The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer. Semin Cancer Biol 2021;72:185-97. [PMID: 33465471 DOI: 10.1016/j.semcancer.2020.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Katayama A, Miligy IM, Shiino S, Toss MS, Eldib K, Kurozumi S, Quinn CM, Badr N, Murray C, Provenzano E, Callagy G, Martyn C, Millican-Slater R, Purdie C, Purnell D, Pinder SE, Oyama T, Shaaban AM, Ellis I, Lee AHS, Rakha EA. Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. Mod Pathol 2021;34:1271-81. [PMID: 33526875 DOI: 10.1038/s41379-021-00738-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
64 Loria R, Vici P, Di Lisa FS, Soddu S, Maugeri-saccà M, Bon G. Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. Front Oncol 2022;12:877380. [DOI: 10.3389/fonc.2022.877380] [Reference Citation Analysis]
65 Li C, Fan H, Xiang Q, Xu L, Zhang Z, Liu Q, Zhang T, Ling J, Zhou Y, Zhao X, Cui Y. Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat 2019;178:497-504. [PMID: 31471838 DOI: 10.1007/s10549-019-05421-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
66 Taha HF, Elfarargy OM, Salem RA, Mandour D, Salem AA, Riad M. Concordance Between ER, PR, HER2 neu Receptors Before and After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Forum of Clinical Oncology 2021;12:3-11. [DOI: 10.2478/fco-2019-0021] [Reference Citation Analysis]